Valero V - Search Results

1

Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials.

Juul N, Szallasi Z, Eklund AC, Li Q, Burrell RA, Gerlinger M, Valero V, Andreopoulou E, Esteva FJ, Symmans WF, Desmedt C, Haibe-Kains B, Sotiriou C, Pusztai L, Swanton C. Juul N, et al. Among authors: valero v. Lancet Oncol. 2010 Apr;11(4):358-65. doi: 10.1016/S1470-2045(10)70018-8. Epub 2010 Feb 26. Lancet Oncol. 2010. PMID: 20189874 Free article.

2

Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer.

Rivera E, Valero V, Esteva FJ, Syrewicz L, Cristofanilli M, Rahman Z, Booser DJ, Hortobagyi GN. Rivera E, et al. Among authors: valero v. Cancer Chemother Pharmacol. 2002 Apr;49(4):299-302. doi: 10.1007/s00280-001-0405-3. Epub 2001 Dec 18. Cancer Chemother Pharmacol. 2002. PMID: 11914909

3

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.

Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, Sneige N, Smith TL, Hortobagyi GN. Esteva FJ, et al. Among authors: valero v. J Clin Oncol. 2002 Apr 1;20(7):1800-8. doi: 10.1200/JCO.2002.07.058. J Clin Oncol. 2002. PMID: 11919237 Clinical Trial.

4

Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer.

Esmaeli B, Hortobagyi GN, Esteva FJ, Booser D, Ahmadi MA, Rivera E, Arbuckle R, Delpassand E, Guerra L, Valero V. Esmaeli B, et al. Among authors: valero v. Ophthalmology. 2002 Jun;109(6):1188-91. doi: 10.1016/s0161-6420(02)00989-2. Ophthalmology. 2002. PMID: 12045065 Clinical Trial.

5

Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer.

Booser DJ, Esteva FJ, Rivera E, Valero V, Esparza-Guerra L, Priebe W, Hortobagyi GN. Booser DJ, et al. Among authors: valero v. Cancer Chemother Pharmacol. 2002 Jul;50(1):6-8. doi: 10.1007/s00280-002-0464-0. Epub 2002 May 21. Cancer Chemother Pharmacol. 2002. PMID: 12111105 Clinical Trial.

6

Global gene expression changes during neoadjuvant chemotherapy for human breast cancer.

Buchholz TA, Stivers DN, Stec J, Ayers M, Clark E, Bolt A, Sahin AA, Symmans WF, Hess KR, Kuerer HM, Valero V, Hortobagyi GN, Pusztai L. Buchholz TA, et al. Among authors: valero v. Cancer J. 2002 Nov-Dec;8(6):461-8. doi: 10.1097/00130404-200211000-00010. Cancer J. 2002. PMID: 12500855

7

Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy.

Buchholz TA, Davis DW, McConkey DJ, Symmans WF, Valero V, Jhingran A, Tucker SL, Pusztai L, Cristofanilli M, Esteva FJ, Hortobagyi GN, Sahin AA. Buchholz TA, et al. Among authors: valero v. Cancer J. 2003 Jan-Feb;9(1):33-41. doi: 10.1097/00130404-200301000-00007. Cancer J. 2003. PMID: 12602766

8

Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors.

Pusztai L, Ayers M, Stec J, Clark E, Hess K, Stivers D, Damokosh A, Sneige N, Buchholz TA, Esteva FJ, Arun B, Cristofanilli M, Booser D, Rosales M, Valero V, Adams C, Hortobagyi GN, Symmans WF. Pusztai L, et al. Among authors: valero v. Clin Cancer Res. 2003 Jul;9(7):2406-15. Clin Cancer Res. 2003. PMID: 12855612

9

A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma.

Esteva FJ, Rivera E, Cristofanilli M, Valero V, Royce M, Duggal A, Colucci P, DeJager R, Hortobagyi GN. Esteva FJ, et al. Among authors: valero v. Cancer. 2003 Sep 1;98(5):900-7. doi: 10.1002/cncr.11557. Cancer. 2003. PMID: 12942555 Free article. Clinical Trial.

10

Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer.

Rivera E, Valero V, Arun B, Royce M, Adinin R, Hoelzer K, Walters R, Wade JL 3rd, Pusztai L, Hortobagyi GN. Rivera E, et al. Among authors: valero v. J Clin Oncol. 2003 Sep 1;21(17):3249-54. doi: 10.1200/JCO.2003.03.111. J Clin Oncol. 2003. PMID: 12947059 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

497 results

Search Page

Filters